Hedrich K, Marder K, Harris J, Kann M, Lynch T, Meija-Santana H, Pramstaller P P, Schwinger E, Bressman S B, Fahn S, Klein C
Department of Neurology, Medical University of Lübeck, Germany.
Neurology. 2002 Apr 23;58(8):1239-46. doi: 10.1212/wnl.58.8.1239.
Early onset PD has been associated with different mutations in the Parkin gene, including exon deletions and duplications.
The authors performed an extensive mutational analysis on 50 probands with onset of PD at younger than 50 years of age. Thirteen probands were ascertained from a registry of familial PD and 37 probands by age at onset at younger than 50 years, blind to family history. Mutational analysis was undertaken on the probands and available family members and included conventional techniques (single strand conformation polymorphism analysis and sequencing) and a newly developed method of quantitative duplex PCR to detect alterations of gene dosage (exon deletions and duplications) in PARKIN:
Using this new technique, the authors detected eight alterations of gene dosage in the probands, whereas 12 mutations were found by conventional methods among the probands and another different mutation in an affected family member. In total, the authors identified compound heterozygous mutations in 14%, heterozygous mutations in 12%, and no Parkin mutation in 74% of the 50 probands. We expanded the occurrence of Parkin mutations to another ethnic group (African-American).
The authors systematically screened all 12 Parkin exons by quantitative PCR and conventional methods in 50 probands. Eight mutations were newly reported, 2 of which are localized in exon 1, and 38% of the mutations were gene dosage alterations. These results underline the need to screen all exons and to undertake gene dosage studies. Furthermore, this study reveals a frequency of heterozygous mutation carriers that may signify a unique mode of inheritance and expression of the Parkin gene.
早发性帕金森病与帕金森基因的不同突变有关,包括外显子缺失和重复。
作者对50名发病年龄小于50岁的帕金森病先证者进行了广泛的突变分析。13名先证者来自家族性帕金森病登记处,37名先证者根据发病年龄小于50岁确定,对家族史不知情。对先证者及其可用的家庭成员进行了突变分析,包括传统技术(单链构象多态性分析和测序)以及一种新开发的定量双链PCR方法,以检测帕金森基因中基因剂量的改变(外显子缺失和重复)。
使用这项新技术,作者在这些先证者中检测到8例基因剂量改变,而通过传统方法在先证者中发现了12个突变,在一名受影响的家庭成员中发现了另一个不同的突变。在这50名先证者中,作者总共鉴定出14%为复合杂合突变,12%为杂合突变,74%未发现帕金森基因突变。我们将帕金森基因突变的发生范围扩大到了另一个种族群体(非裔美国人)。
作者通过定量PCR和传统方法对50名先证者的所有12个帕金森外显子进行了系统筛查。新报告了8个突变,其中2个位于外显子1,38%的突变是基因剂量改变。这些结果强调了筛查所有外显子并进行基因剂量研究的必要性。此外,这项研究揭示了杂合突变携带者的频率,这可能意味着帕金森基因独特的遗传和表达模式。